Drug Profile


Alternative Names: CI 898; JB 11; Neutrexin; NSC 249008; NSC 328564; NSC 352122; Trimetrexate glucuronate

Latest Information Update: 18 Jan 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pfizer
  • Class Antineoplastics; Antiprotozoals; Quinazolines
  • Mechanism of Action Tetrahydrofolate dehydrogenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Marketed Pneumocystis pneumonia
  • Discontinued Bladder cancer; Breast cancer; Cancer; Cervical cancer; Colorectal cancer; Gastric cancer; Leukaemia; Lung cancer; Non-small cell lung cancer; Pancreatic cancer; Psoriasis; Rheumatoid arthritis

Most Recent Events

  • 14 Jan 2010 Biovitrum has merged with Swedish Orphan to form Swedish Orphan Biovitrum
  • 19 Jun 2007 MedImmune has been acquired by AstraZeneca
  • 05 Jun 2003 Beaufour-Ipsen is now called Ipsen
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top